Physician profile
Sayed S Ali
NPI 1194721191
$41,452.80
in general payments reported to CMS, 2019-2025
39 companies · $2,066 in 2025
The $2,066 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,687 · 2020: $11K · 2021: $3,869 · 2022: $12K · 2023: $3,952 · 2024: $1,680 · 2025: $2,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,745 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Consulting Fee: $1,224 · Travel and Lodging: $219 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,744.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Consulting Fee | $1,224.00 |
| Travel and Lodging | $219.18 |
| Education | $210.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $32,123.29 | 2019-2025 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $1,968.64 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $882.15 | 2020-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $787.32 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $693.56 | 2019-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $588.41 | 2019-2025 | Rayaldee |
| Amgen INC. | $391.10 | 2023-2025 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $327.80 | 2021-2025 | |
| Novo Nordisk INC | $323.97 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Ani Pharmaceuticals, INC. | $322.74 | 2022-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $285.02 | 2022-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $275.76 | 2021-2025 | |
| Lilly USA, LLC | $223.78 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $219.02 | 2019-2021 | |
| Akebia Therapeutics INC | $216.31 | 2019-2025 | Vafseo |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.